Explore PhytoZon® Ingredients
RNI249® – Is a Patented, Highly Concentrated Substance:
(Support studies under “Scientific Studies”)
RNI249® Is the only known natural substance or pharmaceutical shown to increase endogenous IGF-1 in human cells
Research supported by two National Institutes of Health: National Institute of Aging and the National Institute of Arthritis and Musculoskeletal Disease
1. Endogenous IGF-1 Secretion
2. Healthy Aging
RNI 249® is a patented extract from the hypocotyls of the crucifer Lepidium meyenii (aka “Maca”), a radish-like tuber cultivated only on the inner slopes of the Andean Mountains. In a study with Case Western Reserve University, it has been shown to increase human cellular production of IGF-1 and in a clinical trial, together with Vincaria®, was an effective treatment for osteoporosis.
The pituitary gland in the brain secretes human growth hormone (HGH) which in turn signals (primarily) the liver to produce and secrete insulin like growth factor 1 (IGF-1). Both HGH and IGF-1 promote whole body growth and their levels peak during puberty. IGF-1 increases protein synthesis (muscle growth), bone mineralization, low blood sugar, kidney function and insulin sensitivity. It promotes healing and repair of bone, muscle, nervous system and immune system cells.
Following puberty when its levels are at their peak, as we age, IGF-1 levels precipitously decline such that by the time we are 60 years old, the levels have decreased by approximately eighty percent (80%).
This natural decline in IGF-1 levels in adulthood, known as somatopause, is responsible for most of the signs we associate with aging. These include but are not limited to altered musculoskeletal function (e.g. muscle atrophy; associated decrease in strength; bone calcium loss/osteoporosis); altered endocrine function (i.e. a higher incidence of diabetes); altered carbohydrate and lipid metabolism; altered Integumentary function (e.g. skin thinning, wrinkles); and, altered neurological function (e.g. dementia, Alzheimer disease).
To date, RNI 249 is the only substance, natural or pharmaceutical, which has been shown to increase the body’s natural production of IGF.
As proof of principle, researchers subsequently conducted a human clinical trial, sponsored in part by the NIH/NIA, in subjects with confirmed osteoarthritis. Within the 30-day period of the trial and then for most within seven days, 94% of the participants had a statistically significant improvement in mobility and flexibility and in comparison to the positive control glucosamine, a marked reduction in pain.
Barzilai N, Huffman D, Muzumdar R et al: The Critical Role of Metabolic Pathways in Aging. Diabetes. 2012. 61(6):1315-1322
Bobrowski P (PI): Enhanced IGF-1 Production in Human Cartilage. Grant No. 1R43AG024733-01, US National Institutes of Health (NIH): National Institute on Aging & National Institute of Arthritis and Musculoskeletal Disease. 2004-2005.
Bobrowski, PJ: Methods and compositions to enhance endogenous IGF production and their use. USPTO No. 8182847: 2012 May 22.
Brugts M, Ranke M, Hofland L et al: Normal Values of Circulating Insulin-Like Growth Factor-I Bioactivity in the Healthy Population: Comparison with Five Widely Used IGF-I Immunoassays. J Clin Endocrinol Metab. 2008. 93(7):2539–2545.
Gong Z, Kennedy O, Sun H et al: Reductions in serum IGF-1 during aging impair health span. Aging Cell. 2014. 13(3):408-18.
Juul A, Bang P, Hertel N at al: Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab. 1994. 78(3):744-52.
Mehta K, Gala J, Bhasale S et al: Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Comp Alt Med. 2007. 7:34.
Miller M, Ahmed S, Bobrowski P et al: The chondroprotective actions of a natural product are associated with the activation of IGF-1 production by human chondrocytes despite the presence of IL-1beta. BMC Complement Altern Med. 2006. 6:13.
Noordam R, Gunn D, Tomlin C et al: Serum insulin-like growth factor 1 and facial ageing: high levels associate with reduced skin wrinkling in a cross-sectional study. Br J Dermatol. 2013. 168(3):533-8.
O’Neill C, Kiely A, Coakley M et al: Insulin and IGF-1 signaling: longevity, protein homoeostasis and Alzheimer’s disease. Biochem Soc Trans. 2012. 40(4):721-7.
Sjögren K, Jansson J, Isaksson O et al: A model for tissue-specific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I. Endocrine. 2002. 19(3):249-56.
Xu S, Gu X, Pan H et al: Reference ranges for serum IGF-1 and IGFBP-3 levels in Chinese children during childhood and adolescence. Endocr J. 2010. 57(3):221-8.